These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Diabetes cure at Vals-les-Bains, based on recent research]. UZAN M Maroc Med; 1951 Mar; 30(310):328-30. PubMed ID: 14851922 [No Abstract] [Full Text] [Related]
7. [The treatment of diabetes at Vals-les-bains]. GIRAUD G; PUECH A Concours Med; 1952 Apr; 74(15):1357-9. PubMed ID: 12979396 [No Abstract] [Full Text] [Related]
8. [Vals-les-Bains cure in diabetics]. UZAN M Vie Med; 1951 Jul; 32(7):67. PubMed ID: 14867203 [No Abstract] [Full Text] [Related]
9. [Diabetic center at the Vals-les-Bains Hospital]. LABORIE P Tech Hosp Med Soc Sanit; 1955 Oct; 11(121):53-4. PubMed ID: 13291238 [No Abstract] [Full Text] [Related]
10. [The effects of water intake from Vals Perles no. 3 on the urinary reaction to di-chlorophenol 1-6 indophenol of pulmonary tuberculosis patients]. MINET J; DUHOT E; FONTAN M Union Med Prat Francais; 1946; 26(7):161-3. PubMed ID: 20285518 [No Abstract] [Full Text] [Related]
11. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. Weycker D; Edelsberg J; Vincze G; Kjeldsen SE; Jamerson K; Khan ZM; Oster G J Hum Hypertens; 2007 May; 21(5):374-80. PubMed ID: 17314999 [TBL] [Abstract][Full Text] [Related]
12. Effect of valsartan on the incidence of diabetes. Luan FL N Engl J Med; 2010 Aug; 363(8):792; author reply 792-3. PubMed ID: 20718670 [No Abstract] [Full Text] [Related]
13. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. Hollenberg NK; Parving HH; Viberti G; Remuzzi G; Ritter S; Zelenkofske S; Kandra A; Daley WL; Rocha R J Hypertens; 2007 Sep; 25(9):1921-6. PubMed ID: 17762658 [TBL] [Abstract][Full Text] [Related]
15. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T Thromb Res; 2006; 117(4):385-92. PubMed ID: 15896827 [TBL] [Abstract][Full Text] [Related]
16. Valsartan increases circulating adiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertension. Lee JM; Kim JH; Son HS; Hong EG; Yu JM; Han KA; Min KW; Chang SA J Int Med Res; 2010; 38(1):234-41. PubMed ID: 20233535 [TBL] [Abstract][Full Text] [Related]
17. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial. Kjeldsen SE; McInnes GT; Mancia G; Hua TA; Julius S; Weber MA; Coca A; Girerd X; Jamerson K; Larochelle P; Macdonald T; Schmieder RE; Anthony Schork M; Viskoper R; Widimsky J; Zanchetti A Blood Press; 2008; 17(3):170-7. PubMed ID: 18608200 [TBL] [Abstract][Full Text] [Related]
18. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Wagstaff AJ Drugs; 2006; 66(14):1881-901. PubMed ID: 17040120 [TBL] [Abstract][Full Text] [Related]
20. Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes. Luzio SD; Dunseath G; Owens DR Horm Metab Res; 2002 May; 34(5):271-4. PubMed ID: 12063642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]